Cargando…

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

SWItch/Sucrose Non-Fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4) mutations are commonly reported in non-small cell lung cancer (NSCLC) and are associated with a poor prognosis. There is insufficient evidence regarding the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koizumi, Akiko, Tamura, Yukiho, Yoshida, Ryohei, Mori, Chie, Ono, Yusuke, Tanino, Mishie, Mizukami, Yusuke, Sasaki, Takaaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188218/ https://www.ncbi.nlm.nih.gov/pubmed/37200668 http://dx.doi.org/10.7759/cureus.37656

Ejemplares similares

SMARCB1 (INI1) retained but SMARCA4 (BRG1) negative atypical teratoid/rhabdoid tumor arising at the bilateral cerebellopontine angles: a case report
por: Mitsui, Nobuyuki, et al.
Publicado: (2021)

Low-grade papillary Schneiderian carcinoma with TP53 mutation: a case report and review of the literature
por: Yuzawa, Sayaka, et al.
Publicado: (2023)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
por: Liberini, Virginia, et al.
Publicado: (2021)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review
por: Sugiyama, Yuya, et al.
Publicado: (2022)

Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profiling during the long-term postoperative course
por: Sato, Hiroki, et al.
Publicado: (2020)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy With Distinct Clinicopathological Characteristics
por: Al-Shbool, Ghassan, et al.
Publicado: (2022)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
por: Brueckl, Wolfgang M., et al.
Publicado: (2020)

Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR
por: Yoshida, Ryohei, et al.
Publicado: (2018)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

EGFR突变NSCLC患者TKIs耐药后ICIs治疗进展
Publicado: (2022)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
por: Chalker, Cameron, et al.
Publicado: (2022)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients
por: Tang, Cuiping, et al.
Publicado: (2022)

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
por: Zhang, Xin, et al.
Publicado: (2022)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas
por: Urer, Halide Nur, et al.
Publicado: (2023)

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
por: Ariyasu, Ryo, et al.
Publicado: (2021)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
por: Chen, Jiamin, et al.
Publicado: (2023)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

Cerebellar Ataxia Caused by Central Nervous System Tuberculosis With Pulmonary Tuberculosis: A Case Report
por: Saishoji, Yusuke, et al.
Publicado: (2023)

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors—retrospective study
por: Higaki, Hajime, et al.
Publicado: (2023)

Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB
por: Kawabata, Hidemasa, et al.
Publicado: (2019)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

The Icy Realm of the Rime
por: Potter, Polyxeni
Publicado: (2011)

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
por: Dong, Yawen, et al.
Publicado: (2021)

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
por: Shi, Congqi, et al.
Publicado: (2022)

High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer
por: Guerrero-Martínez, Jose A., et al.
Publicado: (2018)

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
por: Cantley, Jennifer, et al.
Publicado: (2022)

SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution
por: Sun, Shanshan, et al.
Publicado: (2022)

Transient elastography: a novel, non-invasive method for the evaluation of liver stiffness and controlled attenuation parameter in cows
por: ONO, Mamiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0uv18dm0bfkt8rp54gtr566vq